Asian Science Citation Index is committed to provide an authoritative, trusted and significant information by the coverage of the most important and influential journals to meet the needs of the global scientific community.  
ASCI Database
308-Lasani Town,
Sargodha Road,
Faisalabad, Pakistan
Fax: +92-41-8815544
Contact Via Web
Suggest a Journal
Articles by R Nakamura
Total Records ( 2 ) for R Nakamura
  W Zhou , J Longmate , S. F Lacey , J. M Palmer , G Gallez Hawkins , L Thao , R Spielberger , R Nakamura , S. J Forman , J. A Zaia and D. J. Diamond

Reconstitution of cytomegalovirus (CMV)–specific CD8+ T cells is essential to the control of CMV infection in CMV-positive recipients (R+) after allogeneic hematopoietic stem cell transplantation (HCT). Six-color flow cytometry was used to assess the functional profile of CMV-specific CD8+ T cells in 62 of 178 R+ HCT recipients followed virologically for CMV reactivation. R+ recipients receiving grafts from CMV-negative donors (D; D/R+) reconstituted fewer multifunctional CD8+ T cells expressing tumor necrosis factor- (TNF-), macrophage inflammatory protein-1β (MIP-1β), and CD107 in addition to interferon- (IFN-), compared with D+/R+ recipients. Unlike monofunctional CD8+ T cells secreting IFN-, which were abundantly generated during CMV reactivation in D/R+ recipients, the relative lack of multifunctional CD8+ T cells persisted until at least 1 year post-HCT. D/R+ recipients were more likely to require recurrent and prolonged use of antivirals. These findings were robust to statistical adjustment for pretransplant factors, as well as for posttransplant factors including graft-versus-host disease (GVHD) and its treatment by steroids. These analyses suggest that D+/R+ transplants, on average, generate higher levels of multifunctional CMV-specific T cells and require less antiviral therapy compared with D/R+ HCT recipients. These results highlight the benefit of D+ donors in improving outcomes of R+ HCT recipients by reducing the duration and recurrent need of antiviral treatment, aided by increased levels of multifunctional CMV-specific T cells.

  K Gotoh , Y Tanaka , A Nishikimi , R Nakamura , H Yamada , N Maeda , T Ishikawa , K Hoshino , T Uruno , Q Cao , S Higashi , Y Kawaguchi , M Enjoji , R Takayanagi , T Kaisho , Y Yoshikai and Y. Fukui

Plasmacytoid dendritic cells (pDCs) play a key role in antiviral immunity, but also contribute to the pathogenesis of certain autoimmune diseases, by producing large amounts of type I IFNs. Although activation of pDCs is triggered by engagement of nucleotide-sensing toll-like receptors (TLR) 7 and 9, type I IFN induction additionally requires IB kinase (IKK) –dependent activation of IFN regulatory factor (IRF) 7. However, the signaling pathway mediating IKK- activation is poorly defined. We show that DOCK2, an atypical Rac activator, is essential for TLR7- and TLR9-mediated IFN- induction in pDCs. We found that the exposure of pDCs to nucleic acid ligands induces Rac activation through a TLR-independent and DOCK2-dependent mechanism. Although this Rac activation was dispensable for induction of inflammatory cytokines, phosphorylation of IKK- and nuclear translocation of IRF-7 were impaired in Dock2-deficient pDCs, resulting in selective loss of IFN- induction. Similar results were obtained when a dominant-negative Rac mutant was expressed in wild-type pDCs. Thus, the DOCK2–Rac signaling pathway acts in parallel with TLR engagement to control IKK- activation for type I IFN induction. Owing to its hematopoietic cell-specific expression, DOCK2 may serve as a therapeutic target for type I IFN–related autoimmune diseases.

Copyright   |   Desclaimer   |    Privacy Policy   |   Browsers   |   Accessibility